MedTrace Logo

Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria

NCT02110784 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-09-17

No results posted yet for this study

Summary

The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries.

Conditions

  • Malaria, Vivax

Interventions

DRUG

Eurartesim tablets

dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days

Sponsors & Collaborators

  • Alfasigma S.p.A.

    lead INDUSTRY

Principal Investigators

  • Christoph Hatz, Prof Dr Med · Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute, Basel - Switzerland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-18
Primary Completion
2016-11-23
Completion
2017-04-30

Countries

  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02110784 on ClinicalTrials.gov